Pre-market analysis
1)Nifty closed at 11333.85 down 1.68% and banknifty closed at 23011.50 down 2.21%. 2)Global markets closed negative on friday.Recovery seen in second half in us markets after huge fall in first half. |
3)Today, US and Europe futures are trading mixed and asian markets opened mixed and sgx nifty future is trading at 11336.00 down 0.22%.
4) We may open flat or gap down of around 20-30 pts and follow global futures as the day progresses. We may recover in second half.
5)Support and resistance for Nifty and Banknifty for intraday.
6)Nifty option pain is at 11400 and banknifty option pain is at 23200.
7)Nifty may trade between 11300 and 11600 and banknifty may trade between 22000 and 23500 for this week.this are very strong support and resistances as per oi chain.
8)Results today
GIC Re
Info Edge
CG Powe
GSFC
HOEC
9)Stocks in news.
VODAFONE IDEA
Board approves fund raising of upto 25,000 cr
Voda UK does not intend to put equity into Indian arm
PC today at 11:45 am for a strategic announcement most likely new branding announcement of merged entity
IRCTC
Railways to run 80 new trains from September 12, reservation to start two days prior
JB CHEMICALS: Open Offer co to acquire upto 20.09lk shares at price of 745.6/sh CMP 783.80
REC Arm Gets 10 MW Solar Power Project Order In Rajasthan
DILIP BUILDCON
L-1 Bidder For NHAI Tender
Project cost of Rs 1,905 cr to be completed over 24 months
NMDC
- Raises prices by 300/t
- Cumulative price hike since July: 1,000/t
10)Results
Jubilant Lifesciences Q1FY21*
Revenue down 13.3% to Rs 1,892.2 crore
Net profit down 52.4% to Rs 88 crore
Ebitda down 30.6% to Rs 301.5 crore
Ebitda margin at 15.9% from 19.9%
Pharmaceutical segment revenue down 17.5% to Rs 1,095.8 crore
Life Sciences Ingredients revenue down 8.5% to Rs 738.8 crore
Drug Discovery and Development Solutions revenue up 25.5% to Rs 60.7 crore
All numbers are consolidated and compared on a year-on-year basis
11)Happy Trading
12)Follow our telegram channel 'Optionstraders' for calls on equity and options.

Comments
Post a Comment